

Pelagia Research Library

Der Chemica Sinica, 2013, 4(5):26-31



Synthesis and antimicrobial activity of some new quinazolin-4(3H)-one derivatives

Anantkumar M. Patel*, Dhaval J. Patel, Bhavesh R. Nathani and Kishor S. Pandya

Department of Chemistry, Sir P. T. Science College, Modasa, Gujarat, India

ABSTRACT

Some new substituted 3-((4-(-phenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (III) have been synthesised from different hydrazinyl thiazole derivatives (I) by condensing with 2-methyl-4H-benzo[d][1,3]oxazin-4-one(II). Their chemical structures have been confirmed by IR, 1H NMR, and MASS and by elemental analysis. Investigation of antimicrobial activity of compound was done by the disk diffusion technique. Among the compound with -F, -Cl and $-NO_2$ substitution showed the most favourable antimicrobial activity.

Keywords: Quinazolinone, Hydrazinyl thiazole, antibacterial and antifungal activity.

INTRODUCTION

Quinazolinone and their derivatives constitute an important class of heterocyclic compounds. It is evident from literature that quinazolinone derivatives are known to be associated with broad spectrum of biological activity like antibacterial^{1,10}, anti-inflammatory^{2,11,12}, analgesic³, antiviral⁴, antifungal⁵, antitubercular⁶ and anticancer activity^{7,13}.

Hydrazinyl thiazole derivative shows anticancer activity⁸. Looking at the biological significance of quinazolinone and hydrazinyl thiazole nucleus it was thought to design and synthesize new quinazolinone derivatives and screen them for their antibacterial activity.

MATERIALS AND METHODS

All the melting points were determined by open capillary using V-Scientific Melting Point apparatus and are uncorrected. Purity of compound was checked by TLC on silica Gel-coated plates. IR spectra were recorded in KBr on FTIR Prestige-211 Simadzu spectrophotometer.¹H NMR spectra were recorded on 500 MHz Bruker using CDCl₃/DMSO and Mass spectra were recorded on using EI-MS mode. Elemental analysis was performed on Perkin-Elmer Series 2400.



Synthesis of Hydrazinyl thiazole :(AMP/001-010)

As shown in scheme-I. As literature serve the synthesis of hydrazinyl thiazole derivatives synthesis by the process⁸.

The different substituted benzene were reacted with acetyl chloride in presence of aluminium chloride by friedle craft acylation we get different substituted acetophenone (**a**) further more reaction of them with bromine gives substituted phenacyl bromide(**b**) each of phenacyl bromide subjected to a cyclization with thiosemicarbazide in presence of dioxane to yield corresponding substituted hydrazinyl thiazole(**AMP/001-010**). All these hydrazinyl thiazole derivatives were identified by IR, ¹H NMR and MASS.



Synthesis of Preparation of 2-methyl-4H-benzo[d][1,3]oxazin-4-one:(AMP/A1)

Charge Anthranilic acid(1.0 mmol) in to methylene dichloride(10.0 ml) in to round bottom flask and cool down reaction mass up to 0-5°C temperature then add triethyl amine (2.5 mmol) and stir reaction mass for 30 minutes then slowly add acetyl chloride (1.5 mmol) in to reaction mass within 30 minutes at 0-5°C then raise temperature of reaction mass up to room temperature and maintain reaction mass for another 1 hour after that charge water (10.0 ml) in to reaction mass and stir for 15 minutes then separate lower organic layer and wash it with water (10.0 ml) and distille out solvent from organic layer under vacuum, get solid collect it (A1). As shown in scheme-II.





Synthesis of substituted 3-((4-(-phenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one: (AMP/A101-110)

General Procedure

A mixture of equimolar quantity of different hydrazinyl thiazole derivatives (0.01 mol) AMP/001-010 and 2-methyl-4H-benzo[d][1,3]oxazin-4-one (0.01 mol) in 10 ml of methanol stir for 12 hours at room temperature then charge 50 ml water in to reaction mass then stir for another 1 hour and filter solid mass and wash with water and dry material at 50-60°C.As shown in scheme-III.

Spectral Data

1. 3-((4-(4-fluorophenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A101):

IR (KBr); 3435.34(-N-H stretching), 3078.49(Aromatic -C-H stretching), 1502.60(Aromatic -C=Cstretching), 2928.04(Aliphatic -C-H stretching), 1377.2(Aliphatic -C-H bending), 1583.61(-C=O stretching of carbonyl), 1159.26(-C-F stretching); ¹H NMR (DMSO) ppm: 2.239 (3H, s, -CH₃), 6.983(1H, m, ArH), 7.250-7.192(2H, m, ArH), 7.228(1H, s, ArH), 7.602(1H, m, ArH), 7.907-7.871(2H, m, ArH), 8.005-7.981(1H, m, ArH), 8.752-8.730(1H, d, ArH), 10.454(1H, s, -NH); MS m/z: 371 [M+NH₄]

2. 3-((4-(4-chlorophenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A102):

IR (KBr); 3416.05(-N-H stretching), 3117.07(Aromatic -C-H stretching), 1535.39(Aromatic -C=Cstretching), 2926.11(Aliphatic -C-H stretching), 1400.37(Aliphatic -C-H bending), 1585.54(-C=O stretching of carbonyl), 752.26(C-Cl stretching); ¹H NMR (DMSO) ppm: 2.241 (3H, s, -CH₃), 7.003-6.966 (1H, m, ArH), 7.132 (1H, s, ArH), 7.544-7.445 (2H, m, ArH), 7.662-7.566 (1H, m, ArH), 8.008-7.840 (2H, m, ArH), 8.447 (1H, d, ArH), 8.746-8.725 (1H, d, ArH), 10.482 (1H, s, -NH); MS m/z: 387 $[M+NH_4]$

3. 2-methyl-3-((4-(4-nitrophenyl) thiazol-2-yl) amino) quinazolin-4(3H)-one (AMP/A103):

IR (KBr); 3439.19(-N-H stretching), 3066.92(Aromatic -C-H stretching), 1452.45(Aromatic -C=Cstretching), 2926.11(Aliphatic -C-H stretching), 1342.50(Aliphatic -C-H bending), 1597.11(-C=O stretching of carbonyl), 1506.46(-N-O stretching); ¹H NMR (DMSO) ppm: 2.251 (3H, s, -CH₃), 7.010-6.992(1H, d, ArH), 7.500(1H, s, ArH), 6.632-7.599(1H, m, ArH), 8.130-8.084(2H, m, ArH), 8.260-8.244(1H, m, ArH), 8.290-8.267(2H, m, ArH), 8.729-8.708(1H, d, ArH), 10.6(1H, s, -NH); MS m/z:398 $[M+NH_4]$

4. 2-methyl-3-((4-phenylthiazol-2-yl) amino) quinazolin-4(3H)-one (AMP/A104):

IR (KBr) 3437.26(-N-H stretching), 3063.06(Aromatic –C-H Stretching), 1435.09(Aromatic-C=C-stretching), 2928.04(Aliphatic –C-H stretching), 1379.15(Aliphatic –C-H bending), 1585.54(-C=O stretching of carbonyl); ¹H NMR (DMSO) ppm: 2.204(3H, s, -CH₃), 7.004-6.967(1H, m, ArH), 7.10(1H, s, ArH), 7.224-7.177(1H, m, ArH), 7.307-7.271(2H, m, ArH), 7.420-7.356(1H, m, ArH), 7.869-7.814(2H, m, ArH), 8.010-7.990(1H, m, ArH), 8.770-8.749(1H, d, ArH), 10.472(1H, s, -NH); MS m/z: 353 [M+NH₄]

5. 3-((4-(4-bromophenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A105):

IR (KBr) 3466.20(-N-H stretching), 3115.14(Aromatic –C-H stretching), 1537.32(Aromatic –C=C-stretching), 2928.04(Aliphatic –C-H stretching), 1396.51(Aliphatic –C-H bending), 1583.61(-C=O stretching of carbonyl), 482.22(-C-Br stretching); ¹H NMR (DMSO) ppm: 2.238(3H, s, -CH₃), 6.997-6.960(1H, m, ArH), 7.173(1H, s, ArH), 7.613-7.533(2H, m, ArH), 7.755-7.734(1H, m, ArH), 7.822-7.777(2H, m, ArH), 8.007-7.984(1H, dd, ArH), 8.740-8.719(1H, d, ArH), 10.552(1H, s, -NH); MS m/z: 431 [M+NH₄]

6. 2-methyl-3-((4-(p-tolyl) thiazol-2-yl) amino) quinazolin-4(3H)-one (AMP/A106):

IR (KBr) 3441.12(-N-H stretching), 3115.14(Aromatic –C-H stretching), 1533.46(Aromatic –C=C-stretching), 2918.40(Aliphatic –C-H stretching), 1379.15(Aliphatic –C-H bending), 1585.54(-C=O stretching of carbonyl); ¹H NMR (DMSO) ppm: 2.317(3H, s, -CH₃), 2.348(3H, s, -CH₃), 6.996-6.959(1H, m, ArH), 7.111(1H, s, ArH), 7.213-7.193(2H, m, ArH), 7.620-7.578(1H, m, ArH), 7.52-7.32(2H, m, ArH), 8.006-7.984(1H, m, ArH), 8.763-8.742(1H, m, ArH), 10.486(1H, s, -NH); MS m/z: 367 [M+NH₄]

7. 2-methyl-3-((4-(3-nitrophenyl) thiazol-2-yl) amino) quinazolin-4(3H)-one (AMP/A107):

IR (KBr) 3466.20(-N-H stretching), 3120.93(Aromatic –C-H stretching), 1516.10(Aromatic –C=Cstretching), 2943.47(Aliphatic –C-H stretching), 1346.36(Aliphatic –C-H bending), 1581.68(-C=O stretching of carbonyl), 1533.46(-N-O stretching); ¹H NMR (DMSO) ppm: 2.250(3H, s, -CH₃), 6.741-6.718(1H, m, ArH), 7.216-6.952(1H, m, ArH), 7.422(1H, s, ArH), 7.723-7.592(2H, m, ArH), 8.088-7.993(1H, m, ArH), 8.234-8.116(1H, m, ArH), 10.9(1H, s, -NH); MS m/z: 398 [M+NH₄]

8. 3-((4-(3, 4-difluorophenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A108):

IR (KBr) 3465.15(-N-H stretching), 3123.24(Aromatic –C-H stretching), 1510.32(Aromatic –C=C-stretching), 2943.47(Aliphatic –C-H stretching), 1342.56(Aliphatic –C-H bending), 1585.25(-C=O stretching of carbonyl); ¹H NMR (DMSO) ppm: 2.230(3H, s, -CH₃), 6.975(1H, s, ArH), 7.001(1H, d, ArH), 7.1(1H, d, ArH), 7.213(1H, m, ArH), 7.413-7.600(1H, m, ArH), 8.123-8.24(1H, m, ArH), 8.613-8.631(1H, m, ArH), 10.61(1H, s, -NH); MS m/z: 389 [M+NH₄]

9. 3-((4-(3, 4-dichlorophenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A109):

IR (KBr) 3455.75(-N-H stretching), 3024.54(Aromatic -C-H stretching), 1545.63(Aromatic -C=C-stretching), 2937.35(Aliphatic -C-H Stretching), 1351.23(Aliphatic -C-H bending), 1589.32(-C=O stretching of carbony); ¹H NMR (DMSO) ppm: $2.240(3H, \text{ s}, -CH_3)$, 6.600(1H, s, ArH), 7.271-7.293(1H, d, ArH), 7.403-7.413(1H, m, ArH), 7.613-7.618(1H, d, ArH), 8.013(1H, m, ArH), 8.170-8.210(1H, m, ArH), 8.713-8.719(1H, m, ArH), 10.59(1H, s, -NH); MS m/z: $422[M+NH_4]$

10. 3-((4-(3, 4-dimethylphenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A110):

IR (KBr) 3435.73(-N-H stretching), 3174.94(Aromatic -C-H stretching), 1543.32(Aromatic -C=C-stretching), 2929.40(Aliphatic -C-H stretching), 1341.31(Aliphatic -C-H bending), 1570.29(-C=O stretching of carbony); ¹H NMR (DMSO) ppm: $1.900(3H, s, -CH_3)$, $2.15(6H, s, -CH_3)$, 6.957(1H, m, ArH), 7.135(1H, s, ArH), 7.177(1H, d, ArH), 7.21(1H, d, ArH), 7.310(1H, m, ArH), 7.413-7.418(2H, m, ArH), 7.751-7.73(1H, m, ArH), 10.66(1H, s, -NH); MS m/z: $381 [M+NH_4]$

Table: 1 Physical property of synthesized substituted 3-((4-(-phenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A101-AMP/A110)



Sr. No.	R ₁	R ₂	Molecular Formula	M.P. (⁰ C)	Mol. Weight	Yield (%)	Elemental analysis Found (Calculated)		
							% C	% H	% N
A MID/A 101	F	н	C H EN OS	224 226	352 30	02	61.05	4.02	16.03
AMIT/AIUI	-1.	-11	C181113111405	224-220	552.59	92	(61.35)	(3.72)	(15.90)
AMP/A102	-C1	-H	CueHu:CIN/OS	215-218	368.84	96	58.72	3.63	15.23
AMI /AI02	-CI	-11	C18113CI1405	215-216	500.04	70	(58.61)	(3.55)	(15.19)
A MD/A 103	- NO-	_H	C. H. N.O.S	278-282	370 30	72	57.01	3.49	18.51
AMI/AI03	- 1002	-11	C181113145O3S	278-282	579.59	12	(56.98)	(3.45)	(18.46)
A MD/A 104	тт	тт	CHNOS	205 200	224 20	81	64.70	4.28	16.80
AMIT/A104	-11	-11	C ₁₈ Π ₁₄ Ν ₄ OS	203-209	554.59		(64.65)	(4.22)	(16.75)
A MD/A 105	D.	т	C II D-N OS	205 209	412 20	66	52.25	3.10	13.49
AMIT/A105	-DI	-11	$C_{18}\Pi_{13}\Pi_{14}OS$	303-308	413.29		(52.31)	(3.17)	(13.56)
A MD/A 106	CII	тт	CUNOS	221 222	248 42	0 2	65.45	4.37	19.94
AMP/A100	- СП3	-п	$C_{19}\Pi_{16}\Pi_{4}OS$	221-225	346.42	02	(65.60)	(4.63)	(16.08)
A MD/A 107	п	NO	CUNOS	230-233	379.39	68	57.01	3.48	18.48
AMIT/AIU/	-11	- INO ₂	C18H13IN5O35				(56.98)	(3.45)	(18.46)
AMP/A108	-F	-F	$C_{18}H_{12}F_2N_4OS$	195-198	370.38	80	58.30	3.22	15.09
							(58.37)	(3.27)	(15.13)
AMP/A109	-Cl	-Cl	$C_{18}H_{12}Cl_2N_4OS$	242-244	403.29	78	53.72	3.05	13.96
							(53.61)	(3.0)	(13.89)
AMP/A110	-CH ₃	-CH ₃	$C_{20}H_{18}N_4OS$	237-239	362.45	95	66.37	5.12	15.57
							(66.28)	(5.01)	(15.46)

In Vitro Antimicrobial Activity

Evaluation of antibacterial and antifungal activities was done by the disk diffusion techniqu⁹. The tested compound solution were prepared in dimethylformamide (DMF) and evaluated them for their in vitro antibacterial and antifungal activity against *Bacillus subtillis* NCIM 2250, *Staphylococcus aureus* NCIM 2079, *Escherichia coli* NCIM 2109, *Aspergillus niger* NICM 501 and *Candida albicans* NICM 7431, respectively.

Table: 2 In Vitro antimicrobial activity of substituted 3-((4-(-phenyl) thiazol-2-yl) amino)-2-methylquinazolin-4(3H)-one (AMP/A101-AMP/A110)

Sr. No.	R ₁	R ₂	E-coli	B-Subtillis	S-Aureus	S-Cerevisiae	A-niger				
AMP/A101	-F	-H	++	++	+	++	+				
AMP/A102	-Cl	-H	+	++	++	+	++				
AMP/A103	- NO ₂	-H	+	+	+	++	+				
AMP/A104	-H	-H	+	+	+	++	+				
AMP/A105	-Br	-H	+	++	++	+	++				
AMP/A106	- CH ₃	-H	+	+	+	++	+				
AMP/A107	-H	- NO ₂	+	+	+	++	+				
AMP/A108	-F	-F	++	++	+	+	+				
AMP/A109	-Cl	-Cl	++	+	+	+	++				
AMP/A110	-CH ₃	-CH ₃	++	+	+	+	++				
*Effectively was classified in to three zones on the bases of the diameter of zone of inhibition											
	+++ : Most effective										
		+	+	: Moderate effective							
+ : Slightly effective											
- : Non effective											

All bacteria were grown on Mueller-Hinton agar (Hi media) plates (37°C, 24 h) and fungi were grown on subouraud dextrose agar (Hi media) plates (26°C, 48-72h). The results were established by the presence of clear zone of inhibition around the activity compound.

RESULTS AND DISCUSSION

As many as new ten compounds were synthesized by adopting similar above procedure and then characterized by their physical, analytical and spectral data. The detail of some of the representative compounds are given in the experimental section. Their physical and elemental analysis data are presented in **Table 1**.

The entire synthesized compounds were tested for in vitro antimicrobial activity by the disk diffusion technique. The results are summarized in **Table 2** that includes the activity of reference compound Ampicillin.

The tested compound exhibited mild to moderate antibacterial activity against all three strains of bacteria.

The compound AMP/A 101, AMP/A108, AMP/A109, AMP/A110 shows highest activity

The antifungal activity of the compound was studied for the two pathogenic fungi. Amphotericin B was used as reference for inhibitory activity against fungi.it was observed that compound AMP/A101, AMP/A103, AMP/A104, AMP/A106, AMP/A107 had highest activity against *S*-*Cerevisiae* and AMP/A102, AMP/A105, AMP/A109 and AMP/A110 tested against *E*-*coli* and showed good activity against *A*-*Niger*. It has also observed that compound AMP/A102, AMP/A105, AMP/A108 against *B*-*Subtillis* and compound AMP/A102, AMP/A102, AMP/A105 against *S*-*Aureus*.

CONCLUSION

The antimicrobial study revealed that substitution in the 3rd position of quinazolinone with methyl and 4th position of hydrazinyl thiazole with Fluorine, bromine chlorine or Nitro produced more active compound in a series.

Acknowledgement

The authors are very much thankful to the Principal, Sir P.T. Science College, Modasa for providing necessary facility and guidance and motivation during research work.

REFERENCES

[1] Ashis Kumar Nanda, Subarna Ganguli, Randhir Chakraborty, molecules, 2007; 12: 2413-2426.

[2] Ryn JV,Botting RM, inflamm res 1995; 44: 1-10.

[3] Veerachamy Alagarsamy, Veluchamy muthukumar, Nagendra Pavalarani, Poongavanam Vasanthanathan, Rajappan Revathi, *Synthesis, Biol. Pharm. Bull.* **2003**;26(4); 557-559.

[4] N.C. Desai, N.K. Undavia, P.B. Trivedi, D. Dave, G.D. Vyas, Indian J. Exp. Biol. 36 (1998) 1280-1283.

[5] Guiping Ouyang, Peiquam Zhang, Gangfang Xu, Baoan Song, Song Yang, Linhong Jin, Wei Xue Deyu Hu, Pinglu, zhuo *chem Molecules* **2006**; 11: 383-392.

[6] Pattan SR, Reddy VVK, Manvi FV, Desai BG, Bhat A., Indian journal of chemistry 2006; 45B: 1771-1781.

[7] V. Murugan, N.P. Padmavathy, G.V.S. Ramasarama, S.V. Sharma, B. Suresh. *Indian J. Heterocyclic Chem.* 13 (2003) 143-146.

[8] Wagner, Gerhard; Chorev, Michael; Moerke, Nathan John; Aktas, Huseyin; Halperin, Jose From PCT int. App.l (2006), *WO2006078942 A2 20060727*.

[9] For testing antimicrobial agent in agar media. In: Corian V (Ed) Antibiotics in Laboratory Medicine. 5th ed. Williams and Wilkins, Baltimore. **1991**, 1-16.

[10] G. Nagarajan, S.Kavimani *Der Pharmacia Sinica*, **2010**, 1 (3): 109-116.

[11] Rashmi. P, Laxmiven Katesh. G and Kuntal. H, Der Chemica Sinica, 2011, 2(2):165-171.

[12] B.R. Dravyakar, P. B. Khedekar, *Der Pharma Chemica.*, **2012**, 4, 2, 699-706.

[13] S. Kumar, G. Mishra, P. Singh, K. K. Jha, R. L. Khosa, S.K. Gupta, Der Chemica Sinica., 2011, 2, 4, 36-58.